Skip to main content
OpenTrials
Completed

NCT Number: NCT03508193

Reverse Engineering of Exclusive Enteral Nutrition

Primary: Nutritional therapy in the form of a whole-food based smoothie can be used to induce remission of active Crohn's disease.

Secondary: Consuming a whole foods based smoothie will result in measurable changes to the microbiome of individuals with Crohn's disease and healthy controls.

The specific aims of this proposal are:

1. To develop a whole-food based smoothie, based on principles of the specific carbohydrate diet, that is comparable in macronutrients and micronutrients to formulas used for exclusive enteral nutritional (EEN) therapy in Crohn's disease. 2. To evaluate the ability of a whole-food based smoothie to induce remission of active Crohn's disease. 3. To evaluate changes to the intestinal microbiome in healthy individuals consuming a whole-food based smoothie diet.

Completed

Looking for future studies?

Notify Me

Key information

Age range

8 year–21 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Seattle Children's Hospital

Seattle, Washington, 98105, United States

About this study

This will be an open label, pilot study over 4 weeks in children with newly diagnosed Crohn's disease treated with a smoothie designed to emulate formulas used for exclusive enteral nutritional therapy. In place of formula, whole-foods based smoothie recipes and the food to create the smoothies will be given to each participant/family. The smoothies will be based upon the concept of reverse-engineering of exclusive enteral nutrition (RE-EEN). The smoothie recipes will involve whole foods that can be blenderized to liquid consistency. Similar to the formulas used for EEN, the smoothies will provide calories, protein, fat, and carbohydrates in a distribution to support growth and development.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 8 -21 years old
  • Diagnosis of Crohn's disease within 4 weeks of study entry
  • Active Crohn's disease, as defined by Pediatric Crohn's Disease Activity Index (PCDAI) ≥10.
  • Participant capable of giving informed consent, or if a minor the parent/guardian is capable of giving informed consent

Exclusion criteria

  • History of surgery for Crohn's disease
  • Perianal disease as part of Crohn's disease phenotype
  • Prior treatment with EEN or the specific carbohydrate for Crohn's disease
  • Prior treatment with any immunosuppressive medication (corticosteroids, anti-TNF-alpha agent, azathioprine, methotrexate, etc.)
  • Prior treatment with antibiotics for Crohn's disease
  • Known allergies to any of the food components in the smoothie
  • Admission to hospital due to severity of Crohn's disease and associated symptoms
  • Unwillingness to provide informed consent

Treatment and study plan

Nutritional therapy

Other

Whole-foods based smoothie designed to emulate formulas used in EEN

Primary outcomes

  1. Fecal calprotectin <250 micrograms/gram

    Time frame: 4 weeks

    surrogate marker of intestinal inflammation

Secondary outcomes

  1. Quality of life as measured by IMPACT III Questionnaire

    Time frame: 4 weeks

    validated quality of life measure for pediatric inflammatory bowel disease

Sponsors and collaborators

Lead sponsor

Dale Lee

Other

Registry information

Official study title

Reverse-Engineering of Exclusive Enteral Nutrition (RE-EEN) in Crohn's Disease

Acronym: RE-EEN

Important dates

Study start
2017
Primary completion
2022
Study completion
2022
First posted
Apr 25, 2018
Registry last updated
Nov 21, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.